Achaogen

IPO

Public · South San Francisco, United States · Founded 2002 · $136.0M raised

Founded
2002
Business Model
B2B
Total Funding
$136.0M
Last Round
$136.0M GrantJan 2010
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Achaogen was a late-stage biopharmaceutical company headquartered in South San Francisco, California, committed to the discovery, development, and commercialization of innovative antibacterial agents to treat multi-drug resistant (MDR) gram-negative infections. Its lead product, plazomicin (marketed as Zemdri), was a next-generation aminoglycoside antibiotic engineered to overcome key resistance mechanisms and received FDA approval in 2018 for complicated urinary tract infections. The company received significant funding from BARDA and other government agencies to advance its antibiotic pipeline, but filed for Chapter 11 bankruptcy in April 2019 after struggling to achieve commercial traction, with its assets subsequently acquired by Cipla USA.

Summary

Achaogen is a Biotech company based in South San Francisco, United States, founded in 2002. It has raised $136.0M in total across 2 rounds, most recently a $136.0M Grant round in Jan 2010. Investors include Biomedical Advanced Research and Development Authority (BARDA), 5AM Ventures and Omega Funds.

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPO2014 (est.)

Sign up to see all 3 events

Funding: Series A through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Achaogen on Indexed.vc
<a href="https://indexed.vc/companies/achaogen"><img src="https://indexed.vc/api/badge/company/achaogen" alt="Achaogen on Indexed.vc" width="260" height="76" /></a>